BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36:S237-S244. [PMID: 12407599 DOI: 10.1002/hep.1840360730] [Cited by in Crossref: 336] [Cited by in F6Publishing: 235] [Article Influence: 16.8] [Reference Citation Analysis]
Number Citing Articles
1 Grewal AK, Lopes MB, Berg CL, Bennett AK, Alves VA, Trugman JM. Recurrent demyelinating myelitis associated with hepatitis C viral infection. J Neurol Sci. 2004;224:101-106. [PMID: 15450779 DOI: 10.1016/j.jns.2004.06.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
2 Li PY, Yao L, Guo B, Song JW. Interleukin-28B gene polymorphisms: a new beginning of personalized treatment of hepatitis C. Shijie Huaren Xiaohua Zazhi 2012; 20(2): 119-124 [DOI: 10.11569/wcjd.v20.i2.119] [Reference Citation Analysis]
3 Gupta SK, Sellers E, Somoza E, Angles L, Kolz K, Cutler DL. The effect of multiple doses of peginterferon alfa-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. J Clin Pharmacol 2007;47:604-12. [PMID: 17400820 DOI: 10.1177/0091270007299760] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
4 Gill M, Horn K, Hennan J, White R, Bounous D, Clark S, Megill JR, Janovitz E, Davies M, Sanderson T, Graziano M. From the Cover: Investigative Nonclinical Cardiovascular Safety and Toxicology Studies with BMS-986094, an NS5b RNA-Dependent RNA Polymerase Inhibitor. Toxicol Sci 2017;155:348-62. [PMID: 27864544 DOI: 10.1093/toxsci/kfw211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Cornberg M, Deterding K, Manns MP. Present and future therapy for hepatitis C virus. Expert Rev Anti Infect Ther 2006;4:781-93. [PMID: 17140355 DOI: 10.1586/14787210.4.5.781] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
6 Tanamly MD, Tadros F, Labeeb S, Makld H, Shehata M, Mikhail N, Abdel-Hamid M, Shehata M, Abu-Baki L, Medhat A. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis. 2004;36:752-759. [PMID: 15571006 DOI: 10.1016/j.dld.2004.06.015] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
7 Serrano-Villar S, Quereda C, Moreno A, Pérez-Elías MJ, Casado JL, Royuela A, Dronda F, Navas E, Hermida JM, Moreno S. Neutropenia during therapy with peginterferon and ribavirin in HIV-infected subjects with chronic hepatitis C and the risk of infections. Clin Infect Dis 2013;57:458-64. [PMID: 23575196 DOI: 10.1093/cid/cit221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Ding CZ, Zhang Y, Li X, Liu Y, Zhang S, Zhou Y, Plattner JJ, Baker SJ, Liu L, Duan M, Jarvest RL, Ji J, Kazmierski WM, Tallant MD, Wright LL, Smith GK, Crosby RM, Wang AA, Ni Z, Zou W, Wright J. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease. Bioorganic & Medicinal Chemistry Letters 2010;20:7317-22. [DOI: 10.1016/j.bmcl.2010.10.071] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
9 Manns MP. Adherence to combination therapy: influence on sustained virologic response and economic impact. Gastroenterol Clin North Am. 2004;33:S11-S24. [PMID: 15081100 DOI: 10.1016/j.gtc.2003.12.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
10 Zupin L, Polesello V, Alberi G, Moratelli G, Crocè SL, Masutti F, Pozzato G, Crovella S, Segat L. MBL2 Genetic Variants in HCV Infection Susceptibility, Spontaneous Viral Clearance and Pegylated Interferon Plus Ribavirin Treatment Response. Scand J Immunol 2016;84:61-9. [PMID: 27136459 DOI: 10.1111/sji.12444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
11 Gupta SP, Samanta S, Masand N, Patil VM. k nearest neighbor-molecular field analysis on human HCV NS5B polymerase inhibitors: 2,5-disubstituted imidazo[4,5-c]pyridines. Med Chem Res 2013;22:330-9. [DOI: 10.1007/s00044-012-0033-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
12 Innes H, Goldberg D, Dillon J, Hutchinson SJ. Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? Gut 2015;64:1800-9. [DOI: 10.1136/gutjnl-2014-308166] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
13 Hino K, Murakami Y, Nagai A, Kitase A, Hara Y, Furutani T, Ren F, Yamaguchi Y, Yutoku K, Yamashita S, Okuda M, Okita M, Okita K. 417–2α-Tocopherol and ascorbic acid attenuates the ribavirin-induced decrease of eicosapentaenoic acid in erythrocyte membrane in chronic hepatitis C patients. J Gastroenterol Hepatol 2006;21:1269-75. [DOI: 10.1111/j.1440-1746.2006.04378.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
14 Asnis GM, De La Garza R 2nd. Interferon-induced depression: strategies in treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:808-18. [PMID: 15907352 DOI: 10.1016/j.pnpbp.2005.03.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
15 Cadranel JF, Boujenah JL, Bourlière M, Fontanges T, Pol S, Trepo C, Ouzan D. Satisfaction of patients treated for chronic hepatitis C with the peginterferon alfa-2b pen device: the VISA observational study. Gastroenterol Clin Biol 2007;31:180-4. [PMID: 17347628 DOI: 10.1016/s0399-8320(07)89352-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, Wu CY. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:495-503. [PMID: 25398770 DOI: 10.1136/gutjnl-2014-308163] [Cited by in Crossref: 155] [Cited by in F6Publishing: 137] [Article Influence: 19.4] [Reference Citation Analysis]
17 Phillips KD, Brewer R. Pathophysiology of Hepatitis C and HIV Coinfection. Journal of the Association of Nurses in AIDS care 2003;14:27S-51S. [DOI: 10.1177/1055329003254855] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
18 Luo Y, Jin C, Ling Z, Mou X, Zhang Q, Xiang C. Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis. Gene 2013;513:292-6. [DOI: 10.1016/j.gene.2012.10.030] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
19 Lee DU, Je SH, Yoo SJ, Kwon T, Shin JY, Byun JJ, Park JH, Jeong KW, Ku JM, Lyoo YS. Hematological adverse effects and pharmacokinetics of ribavirin in pigs following intramuscular administration. J Vet Pharmacol Ther 2017;40:561-8. [PMID: 28205288 DOI: 10.1111/jvp.12394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
20 Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, Heathcote J, Edwards AM, McGilvray ID. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology. 2005;128:1437-1444. [PMID: 15887125 DOI: 10.1053/j.gastro.2005.01.059] [Cited by in Crossref: 352] [Cited by in F6Publishing: 335] [Article Influence: 20.7] [Reference Citation Analysis]
21 Hsu CS, Liu CH, Liu CJ, Wang CC, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am J Gastroenterol. 2009;104:598-604. [PMID: 19262519 DOI: 10.1038/ajg.2008.125] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
22 George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012;135:44-53. [PMID: 22484806 DOI: 10.1016/j.pharmthera.2012.03.006] [Cited by in Crossref: 111] [Cited by in F6Publishing: 102] [Article Influence: 11.1] [Reference Citation Analysis]
23 Mohanty A, Erqou S, Mcginnis KA, Vanasse G, Freiberg MS, Sherman KE, Butt AA. Therapy for Hepatitis C Virus Infection Increases Survival of Patients With Pretreatment Anemia. Clinical Gastroenterology and Hepatology 2013;11:741-747.e3. [DOI: 10.1016/j.cgh.2013.01.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
24 Gong J, Eley T, He B, Arora V, Philip T, Jiang H, Easter J, Humphreys WG, Iyer RA, Li W. Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans. Xenobiotica 2016;46:52-64. [PMID: 26153443 DOI: 10.3109/00498254.2015.1048487] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
25 Saiz de la Hoya-zamácola P, Marco-mouriño A, Clemente-ricote G, Portilla-sogorb J, Boix-martínez V, Núñez-martínez Ó, Reus-bañuls S, Teixidó i Pérez N. Recomendaciones de expertos sobre el diagnóstico y tratamiento de la hepatitis C crónica en el medio penitenciario. Gastroenterología y Hepatología 2006;29:551-9. [DOI: 10.1157/13094351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
26 Kryger MB, Wohl BM, Smith AA, Zelikin AN. Macromolecular prodrugs of ribavirin combat side effects and toxicity with no loss of activity of the drug. Chem Commun (Camb) 2013;49:2643-5. [PMID: 23431562 DOI: 10.1039/c3cc00315a] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
27 Hermos JA, Quach L, Gagnon DR, Weber HC, Altincatal A, Cho K, Lawler EV, Grotzinger KM. Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection. Pharmacoepidemiol Drug Saf 2014;23:480-8. [PMID: 24677630 DOI: 10.1002/pds.3585] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
28 Buti M, Esteban R. 1990-2010: two decades of interferon-based therapy. Clin Liver Dis 2011;15:473-82. [PMID: 21867931 DOI: 10.1016/j.cld.2011.05.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
29 Soriano V, Martin-Carbonero L, Vispo E, Labarga P, Barreiro P. [Human immunodeficiency virus infection and viral hepatitis]. Enferm Infecc Microbiol Clin. 2011;29:691-701. [PMID: 21978797 DOI: 10.1016/j.eimc.2011.07.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
30 Bourliere M. Traitement de l’hépatite C : gestion des effets secondaires. Gastroentérologie Clinique et Biologique 2008;32:S166-71. [DOI: 10.1016/j.gcb.2008.04.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Corcoran CP. Neuropsychiatric changes in HIV/hepatitis C coinfected patients undergoing interferon therapy. J Assoc Nurses AIDS Care 2003;14:80S-6S. [PMID: 14571562 DOI: 10.1177/1055329003255589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
32 Chen L, Borozan I, Sun J, Guindi M, Fischer S, Feld J, Anand N, Heathcote J, Edwards AM, McGilvray ID. Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology. 2010;138:1123-1133.e1-3. [PMID: 19900446 DOI: 10.1053/j.gastro.2009.10.046] [Cited by in Crossref: 81] [Cited by in F6Publishing: 85] [Article Influence: 6.2] [Reference Citation Analysis]
33 Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231-264; quiz 214-217. [PMID: 16401486 DOI: 10.1053/j.gastro.2005.11.010] [Cited by in Crossref: 261] [Cited by in F6Publishing: 246] [Article Influence: 16.3] [Reference Citation Analysis]
34 Li X, Zhang Y, Liu Y, Ding CZ, Li Q, Zhou Y, Plattner JJ, Baker SJ, Qian X, Fan D, Liao L, Ni Z, White GV, Mordaunt JE, Lazarides LX, Slater MJ, Jarvest RL, Thommes P, Ellis M, Edge CM, Hubbard JA, Somers D, Rowland P, Nassau P, Mcdowell B, Skarzynski TJ, Kazmierski WM, Grimes RM, Wright LL, Smith GK, Zou W, Wright J, Pennicott LE. Synthesis and evaluation of novel α-amino cyclic boronates as inhibitors of HCV NS3 protease. Bioorganic & Medicinal Chemistry Letters 2010;20:3550-6. [DOI: 10.1016/j.bmcl.2010.04.129] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
35 Rosel L, Blanco JR, Metota L, Antonio Oteo J. Lesión necrótica en un paciente con una hepatopatía por el virus de la hepatitis C en tratamiento con interferón pegilado. Enfermedades Infecciosas y Microbiología Clínica 2004;22:497-8. [DOI: 10.1016/s0213-005x(04)73145-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Cheng EY, Saab S, Holt CD, Busuttil RW. Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection. Expert Opinion on Pharmacotherapy 2015;16:2835-48. [DOI: 10.1517/14656566.2015.1114099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
37 Mizokami M. Discovery of critical host factor, IL-28B, associated with response to hepatitis C virus treatment. J Gastroenterol Hepatol. 2012;27:425-429. [PMID: 22168813 DOI: 10.1111/j.1440-1746.2011.07054.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
38 Gonçalves LL, Farias AQ, Gonçalves PL, D’Amico EA, Carrilho FJ. Branch retinal vein thrombosis and visual loss probably associated with pegylated interferon therapy of chronic hepatitis C. World J Gastroenterol 2006; 12(28): 4602-4603 [PMID: 16874884 DOI: 10.3748/wjg.v12.i28.4602] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
39 Tripathi RL, Krishnan P, He Y, Middleton T, Pilot-Matias T, Chen CM, Lau DT, Lemon SM, Mo H, Kati W, Molla A. Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera. Antiviral Res 2007;73:40-9. [PMID: 16914212 DOI: 10.1016/j.antiviral.2006.07.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
40 Bagheri H, Fouladi A, Barange K, Lapeyre-mestre M, Payen J, Montastruc JL, Vinel J. Follow-up of Adverse Drug Reactions from Peginterferon alfa-2b–Ribavirin Therapy. Pharmacotherapy 2004;24:1546-53. [DOI: 10.1592/phco.24.16.1546.50947] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
41 Souvignet C, Lejeune O, Trepo C. Interferon-based treatment of chronic hepatitis C. Biochimie 2007;89:894-8. [PMID: 17570576 DOI: 10.1016/j.biochi.2007.04.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
42 Lötsch J, Hofmann WP, Schlecker C, Zeuzem S, Geisslinger G, Ultsch A, Doehring A. Single and combined IL28B , ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy. Pharmacogenomics 2011;12:1729-40. [DOI: 10.2217/pgs.11.99] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
43 European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392-420. [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003] [Cited by in Crossref: 600] [Cited by in F6Publishing: 564] [Article Influence: 66.7] [Reference Citation Analysis]
44 Weitzman G, Jacobson I. Peginterferon α-2b in the treatment of hepatitis C. Future Virology 2006;1:279-92. [DOI: 10.2217/17460794.1.3.279] [Reference Citation Analysis]
45 Raboisson P, Lenz O, Lin TI, Surleraux D, Chakravarty S, Scholliers A, Vermeiren K, Delouvroy F, Verbinnen T, Simmen K. Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors. Bioorg Med Chem Lett 2007;17:1843-9. [PMID: 17289388 DOI: 10.1016/j.bmcl.2007.01.046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
46 Saiz de la Hoya-Zamácola P, Marco-Mouriño A, Clemente-Ricote G, Portilla-Sogorb J, Boix-Martínez V, Núñez-Martínez O, Reus-Bañuls S, Teixidó i Pérez N. [Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting]. Enferm Infecc Microbiol Clin 2006;24:568-75. [PMID: 17125677 DOI: 10.1157/13093878] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
47 Tanaka Y. Interleukin28B and inosine triphosphatase help to personalize hepatitis C treatment. Digestion. 2011;84:50-55. [PMID: 22156486 DOI: 10.1159/000333214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Thevenot T, Di Martino V, Lunel-fabiani F, Vanlemmens C, Becker M, Bronowicki J, Bresson-hadni S, Miguet J. Traitements complémentaires de l’hépatite chronique virale C. Gastroentérologie Clinique et Biologique 2006;30:197-214. [DOI: 10.1016/s0399-8320(06)73154-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
49 Tuma P, Vispo E, Barreiro P, Soriano V. [Role of tenofovir in HIV and hepatitis C virus coinfection]. Enferm Infecc Microbiol Clin 2008;26 Suppl 8:31-7. [PMID: 19195436 DOI: 10.1157/13126270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
50 Rance J, Newland J, Hopwood M, Treloar C. The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics. Soc Sci Med 2012;74:245-53. [PMID: 22133583 DOI: 10.1016/j.socscimed.2011.10.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
51 Chang SC, Ko WS, Wu SS, Peng CY, Yang SS. Factors associated with quality of life in chronic hepatitis C patients who received interferon plus ribavirin therapy. J Formos Med Assoc 2008;107:454-62. [PMID: 18583216 DOI: 10.1016/S0929-6646(08)60153-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
52 Pol S, Mallet VO. Improving anti-hepatitis C virus therapy. Expert Opin Biol Ther. 2006;6:923-933. [PMID: 16918259 DOI: 10.1517/14712598.6.9.923] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
53 Arizcorreta A, Brun F, Fernández-gutiérrez C, García Juárez R, Guerrero F, Pérez-guzmán E, Girón-gonzález J. Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon. Clinical Microbiology and Infection 2004;10:1067-74. [DOI: 10.1111/j.1469-0691.2004.01023.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
54 Chen XF, Zhao X, Yang Z. Aptamer-Based Antibacterial and Antiviral Therapy against Infectious Diseases. J Med Chem 2021;64:17601-26. [PMID: 34854680 DOI: 10.1021/acs.jmedchem.1c01567] [Reference Citation Analysis]
55 Nelson DR, Davis GL, Jacobson I, Everson GT, Fried MW, Harrison SA, Hassanein T, Jensen DM, Lindsay KL, Terrault N, Zein N. Hepatitis C virus: a critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol 2009;7:397-414; quiz 366. [PMID: 19114127 DOI: 10.1016/j.cgh.2008.11.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
56 Nogueira JB, Sena LC, Quintans Jde S, Almeida JR, França AV, Júnior LJ. Side effects of the therapy with peginterferon and ribavirin in chronic hepatitis C: a small audit. J Pharm Pract 2012;25:85-8. [PMID: 21940604 DOI: 10.1177/0897190011415687] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
57 Dawson MA, Mccarthy PH, Walsh ME, Mclean CA, Thomson K, Roberts S, Street AM. Transjugular liver biopsy is a safe and effective intervention to guide management for patients with a congenital bleeding disorder infected with hepatitis C: Transjugular liver biopsy in CBD. Internal Medicine Journal 2005;35:556-9. [DOI: 10.1111/j.1445-5994.2005.00877.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
58 European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199-236. [PMID: 25911336 DOI: 10.1016/j.jhep.2015.03.025] [Cited by in Crossref: 814] [Cited by in F6Publishing: 766] [Article Influence: 116.3] [Reference Citation Analysis]
59 Pellicano R, Craxì A, Almasio PL, Valenza M, Venezia G, Alberti A, Boccato S, Demelia L, Sorbello O, Picciotto A, Torre F, Ideo G, Cattaneo C, Berrutti M, Rizzetto M. Interferon β-1a alone or in combination with ribavirin: A randomized trial to compare efficacy and safety in chronic hepatitis C. World J Gastroenterol 2005; 11(29): 4484-4489 [PMID: 16052676 DOI: 10.3748/wjg.v11.i29.4484] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
60 Sauer A, Lenoble P, Bader P, Speeg-Schatz C, Bourcier T, Nasica X. [Ocular complications of hepatitis C treatment]. J Fr Ophtalmol 2007;30:e20. [PMID: 17878818 DOI: 10.1016/s0181-5512(07)91366-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
61 White PW, Llinas-Brunet M, Bös M. Blunting the Swiss army knife of hepatitis C virus: inhibitors of NS3/4A protease. Prog Med Chem 2006;44:65-107. [PMID: 16697895 DOI: 10.1016/S0079-6468(05)44402-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Primo Vera J. Diabetes mellitus tipo 1 inducida por interferón pegilado en 2 pacientes con hepatitis crónica c. Gastroenterología y Hepatología 2004;27:69. [DOI: 10.1016/s0210-5705(03)79089-x] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
63 Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B, Gane E, Schuchmann M, Lohse A, Pol S. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology. 2011;141:2047-2055; quiz e14. [PMID: 21925126 DOI: 10.1053/j.gastro.2011.08.051] [Cited by in Crossref: 108] [Cited by in F6Publishing: 99] [Article Influence: 9.8] [Reference Citation Analysis]
64 Jafri S, Gordon SC. Care of the Cirrhotic Patient. Infectious Disease Clinics of North America 2012;26:979-94. [DOI: 10.1016/j.idc.2012.08.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
65 Matthews SC, Paulus MP, Dimsdale JE. Contribution of functional neuroimaging to understanding neuropsychiatric side effects of interferon in hepatitis C. Psychosomatics 2004;45:281-6. [PMID: 15232040 DOI: 10.1176/appi.psy.45.4.281] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
66 Hashemi N, Rossi S, Navarro VJ, Herrine SK. Safety of peginterferon in the treatment of chronic hepatitis C. Expert Opin Drug Saf. 2008;7:771-781. [PMID: 18983223 DOI: 10.1517/14740330802423291] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
67 Akimov S, Adeyemi OM. Peginterferon-α 2a in the treatment of chronic hepatitis C. Future Virology 2006;1:689-701. [DOI: 10.2217/17460794.1.6.689] [Reference Citation Analysis]
68 Ruiz-Sancho A, Soriano V. [HIV and HCV coinfection]. Enferm Infecc Microbiol Clin 2006;24:335-45; quiz 346. [PMID: 16762261 DOI: 10.1157/13089670] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
69 Jonas MC, Rodriguez CV, Redd J, Sloane DA, Winston BJ, Loftus BC. Streamlining Screening to Treatment: The Hepatitis C Cascade of Care at Kaiser Permanente Mid-Atlantic States. Clin Infect Dis 2016;62:1290-6. [PMID: 26908812 DOI: 10.1093/cid/ciw086] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
70 Hamza I, Eid Y, El-Sayed M, Marzaban R, Abdul-Kareem S. Thyroid Dysfunction in Chronic Hepatitis C Patients Treated with the Combined Pegylated Interferon-Ribavirin Therapy. J Interferon Cytokine Res 2016;36:527-33. [PMID: 27333271 DOI: 10.1089/jir.2016.0007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
71 Wedemeyer H, Jäckel E, Wiegand J, Cornberg M, Manns MP. Whom When How Another piece of evidence for early treatment of acute hepatitis C. Hepatology. 2004;39:1201-1203. [PMID: 15122747 DOI: 10.1002/hep.20221] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
72 Li Y, Li S, Duan X, Liu B, Yang C, Zeng P, McGilvray I, Chen L. Activation of endogenous type I IFN signaling contributes to persistent HCV infection. Rev Med Virol 2014;24:332-42. [PMID: 24806972 DOI: 10.1002/rmv.1795] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
73 Hung C, Lee C, Lu S, Wang J, Chen C, Hu T, Kee K, Chang K, Tseng P, Yen Y, Changchien C. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. Liver Int 2006;26:1079-86. [DOI: 10.1111/j.1478-3231.2006.01354.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
74 Xue W, Jiao P, Liu H, Yao X. Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598. Antiviral Res 2014;104:40-51. [PMID: 24462692 DOI: 10.1016/j.antiviral.2014.01.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
75 Simón-Talero M, Buti M, Esteban R. Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction? J Viral Hepat 2012;19 Suppl 1:14-7. [PMID: 22233409 DOI: 10.1111/j.1365-2893.2011.01521.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
76 Adams S, Ostermeier M. Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C. Optometry - Journal of the American Optometric Association 2010;81:580-6. [DOI: 10.1016/j.optm.2010.04.094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
77 Simon RE, Pearson SD, Hur C, Chung RT. Tackling the hepatitis C cost problem: A test case for tomorrow's cures. Hepatology 2015;62:1334-6. [PMID: 26359645 DOI: 10.1002/hep.28157] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
78 Klein MB, Lee T, Brouillette M, Sheehan NL, Walmsley S, Wong DK, Conway B, Hull M, Cooper C, Haidar S, Vezina S, Annable L, Young S, Zubyk W, Singer J; for the CTN194 (PICCO) Investigators. Citalopram for the Prevention of Depression and Its Consequences in HIV-Hepatitis C Coinfected Individuals Initiating Pegylated Interferon/Ribavirin Therapy: A Multicenter Randomized Double-Blind Placebo-Controlled Trial. HIV Clinical Trials 2014;15:161-75. [DOI: 10.1310/hct1504-161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
79 Nicot F, Alric L, Barange K, Métivier S, Dramard JM, Combis JM, Castan B, Meurisse JJ, Payen JL, Garipuy D. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy. J Med Virol. 2011;83:437-444. [PMID: 21264864 DOI: 10.1002/jmv.21976] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
80 Romano KP, Ali A, Aydin C, Soumana D, Ozen A, Deveau LM, Silver C, Cao H, Newton A, Petropoulos CJ. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 2012;8:e1002832. [PMID: 22910833 DOI: 10.1371/journal.ppat.1002832] [Cited by in Crossref: 149] [Cited by in F6Publishing: 123] [Article Influence: 14.9] [Reference Citation Analysis]
81 Nilsson M, Belfrage AK, Lindström S, Wähling H, Lindquist C, Ayesa S, Kahnberg P, Pelcman M, Benkestock K, Agback T, Vrang L, Terelius Y, Wikström K, Hamelink E, Rydergård C, Edlund M, Eneroth A, Raboisson P, Lin T, de Kock H, Wigerinck P, Simmen K, Samuelsson B, Rosenquist Å. Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: Exploration of P2 quinazoline substituents. Bioorganic & Medicinal Chemistry Letters 2010;20:4004-11. [DOI: 10.1016/j.bmcl.2010.05.029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
82 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-264. [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023] [Cited by in Crossref: 847] [Cited by in F6Publishing: 805] [Article Influence: 77.0] [Reference Citation Analysis]
83 Teoh NC, Farrell GC. Management of chronic hepatitis C virus infection: a new era of disease control. Intern Med J. 2004;34:324-337. [PMID: 15228394 DOI: 10.1111/j.1445-5994.2004.00615.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
84 Fontanges T, Beorchia S, Douvin C, Delassalle P, Combis J, Hanslik B, Jacques J, Filoche B, Desmorat H, Chandelier C, Ouzan D. Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infection. Gastroentérologie Clinique et Biologique 2007;31:566-72. [DOI: 10.1016/s0399-8320(07)89432-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
85 Pastore F, Martocchia A, Stefanelli M, Prunas P, Giordano S, Toussan L, Devito A, Falaschi P. Hepatitis C virus infection and thyroid autoimmune disorders: A model of interactions between the host and the environment. World J Hepatol 2016; 8(2): 83-91 [PMID: 26807204 DOI: 10.4254/wjh.v8.i2.83] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
86 Fattovich G, Zagni I, Minola E, Felder M, Rovere P, Carlotto A, Suppressa S, Miracolo A, Paternoster C, Rizzo C. A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. J Hepatol. 2003;39:843-849. [PMID: 14568269 DOI: 10.1016/s0168-8278(03)00391-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
87 Moriyama M, Arakawa Y. Treatment of interferon-α for chronic hepatitis C. Expert Opinion on Pharmacotherapy 2006;7:1163-79. [DOI: 10.1517/14656566.7.9.1163] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
88 Ahmed A, Keeffe EB. Update on chronic hepatitis C. Compr Ther 2003;29:224-32. [PMID: 14989044 DOI: 10.1007/s12019-003-0026-3] [Reference Citation Analysis]
89 Uchiyama S, Keller N, Schlaepfer E, Grube C, Schuepbach RA, Speck RF, Zinkernagel AS. Interferon α-Enhanced Clearance of Group A Streptococcus Despite Neutropenia. J Infect Dis 2016;214:321-8. [PMID: 27338768 DOI: 10.1093/infdis/jiw157] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
90 Alfageme Michavila I, Merino Sánchez M, Pérez Ronchel J, Lara Lara I, Suárez García E, López Garrido J. Sarcoidosis tras tratamiento con interferón y ribavirina. Presentación de un caso y revisión de la bibliografía. Archivos de Bronconeumología 2004;40:45-9. [DOI: 10.1016/s0300-2896(04)75470-8] [Cited by in Crossref: 9] [Article Influence: 0.5] [Reference Citation Analysis]
91 Wadood A, Riaz M, Jamal SB, Shah M. Interactions of ketoamide inhibitors on HCV NS3/4A protease target: molecular docking studies. Mol Biol Rep 2014;41:337-45. [DOI: 10.1007/s11033-013-2867-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
92 Shaheen MA, Idrees M. Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. World J Hepatol 2015; 7(3): 616-627 [PMID: 25848486 DOI: 10.4254/wjh.v7.i3.616] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
93 Stansfield I, Ercolani C, Mackay A, Conte I, Pompei M, Koch U, Gennari N, Giuliano C, Rowley M, Narjes F. Tetracyclic indole inhibitors of hepatitis C virus NS5B-polymerase. Bioorganic & Medicinal Chemistry Letters 2009;19:627-32. [DOI: 10.1016/j.bmcl.2008.12.068] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
94 Morikawa H, Kozuka R, Fujii H, Iwai S, Enomoto M, Tamori A, Saito S, Kawada N. Combination therapy of natural human interferon-beta and ribavirin for chronic hepatitis C patients with injection drug use. Hepatol Res 2013;43:1013-9. [PMID: 23534954 DOI: 10.1111/hepr.12066] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Wang AX, Chen J, Zhao Q, Sun LQ, Friborg J, Yu F, Hernandez D, Good AC, Klei HE, Rajamani R, Mosure K, Knipe JO, Li D, Zhu J, Levesque PC, McPhee F, Meanwell NA, Scola PM. Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus. Bioorg Med Chem Lett 2017;27:590-6. [PMID: 28011221 DOI: 10.1016/j.bmcl.2016.12.013] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
96 Wang BY, Chang HH, Chen IM, Shih CC, Yang AH. Peginterferon alpha-2b and acute allograft failure in a heart transplant recipient. Ann Thorac Surg. 2010;89:1645-1647. [PMID: 20417802 DOI: 10.1016/j.athoracsur.2009.09.084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
97 Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int 2017;37:778-93. [PMID: 27860293 DOI: 10.1111/liv.13317] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 11.0] [Reference Citation Analysis]
98 Wang R, Duan YL. Progress in understanding the role of leptin in the pathogenesis and treatment of chronic hepatitis C. Shijie Huaren Xiaohua Zazhi 2012; 20(10): 831-836 [DOI: 10.11569/wcjd.v20.i10.831] [Reference Citation Analysis]
99 Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, Kim BK, Kim SU, Ahn SH, Han KH. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci. 2015;60:573-581. [PMID: 25236421 DOI: 10.1007/s10620-014-3361-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
100 Liangpunsakul S, Kwo PY. Ushering in an Era Where No Group Who Wants to Be Treated Should Be Excluded. Clin Gastroenterol Hepatol 2017;15:289-91. [PMID: 27650325 DOI: 10.1016/j.cgh.2016.09.014] [Reference Citation Analysis]
101 Thitinan S, McConville JT. Interferon alpha delivery systems for the treatment of hepatitis C. Int J Pharm 2009;369:121-35. [PMID: 19103271 DOI: 10.1016/j.ijpharm.2008.11.027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
102 Fioravante M, Alegre SM, Marin DM, Lorena SL, Pereira TS, Soares EC. Weight loss and resting energy expenditure in patients with chronic hepatitis C before and during standard treatment. Nutrition 2012;28:630-4. [PMID: 22196981 DOI: 10.1016/j.nut.2011.08.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
103 Hartling HJ, Gaardbo JC, Ronit A, Salem M, Laye M, Clausen MR, Skogstrand K, Gerstoft J, Ullum H, Nielsen SD. Impaired Thymic Output in Patients with Chronic Hepatitis C Virus Infection. Scand J Immunol 2013;78:378-86. [DOI: 10.1111/sji.12096] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
104 Hsu CS, Hsu SJ, Lin HH, Tseng TC, Wang CC, Chen DS, Kao JH. A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. J Formos Med Assoc. 2014;113:716-721. [PMID: 24974131 DOI: 10.1016/j.jfma.2014.05.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
105 Toniutto P, Fabris C, Pirisi M. Antiviral treatment of hepatitis C. Expert Opin Pharmacother 2006;7:2025-35. [PMID: 17020430 DOI: 10.1517/14656566.7.15.2025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
106 Dove LM, Rosen RC, Ramcharran D, Wahed AS, Belle SH, Brown RS, Hoofnagle JH. Decline in Male Sexual Desire, Function, and Satisfaction During and After Antiviral Therapy for Chronic Hepatitis C. Gastroenterology 2009;137:873-884.e1. [DOI: 10.1053/j.gastro.2009.05.060] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
107 Tani H, Akimitsu N, Fujita O, Matsuda Y, Miyata R, Tsuneda S, Igarashi M, Sekiguchi Y, Noda N. High-throughput screening assay of hepatitis C virus helicase inhibitors using fluorescence-quenching phenomenon. Biochemical and Biophysical Research Communications 2009;379:1054-9. [DOI: 10.1016/j.bbrc.2009.01.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
108 Savic D, Stojiljkovic M, Lavrnja I, Parabucki A, Bjelobaba I, Nedeljkovic N, Herdegen T, Pekovic S. Ribavirin shows immunomodulatory effects on activated microglia. Immunopharmacology and Immunotoxicology 2014;36:433-41. [DOI: 10.3109/08923973.2014.971962] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
109 McHutchison JG, Manns MP, Longo DL. Definition and management of anemia in patients infected with hepatitis C virus. Liver Int 2006;26:389-98. [PMID: 16629641 DOI: 10.1111/j.1478-3231.2006.01228.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
110 Hsu CS, Kao JH. Management of hepatitis C patients with decompensated liver disease. Expert Rev Gastroenterol Hepatol 2016;10:679-88. [PMID: 26782619 DOI: 10.1586/17474124.2016.1143775] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
111 D'Avolio A, De Nicolò A, Simiele M, Turini S, Agnesod D, Boglione L, Cusato J, Baietto L, Cariti G, Calcagno A, Sciandra M, Di Perri G, Bonora S. Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. J Pharm Biomed Anal 2012;66:376-80. [PMID: 22513116 DOI: 10.1016/j.jpba.2012.03.030] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
112 Malaguarnera M, Vacante M, Giordano M, Motta M, Bertino G, Pennisi M, Neri S, Malaguarnera M, Volti GL, Galvano F. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin. World J Gastroenterol 2011; 17(39): 4414-4420 [PMID: 22110268 DOI: 10.3748/wjg.v17.i39.4414] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
113 Gupta R, Ramakrishna C, Lakhtakia S, Tandan M, Banerjee R, Reddy DN. Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C. World J Gastroenterol 2006; 12(34): 5554-5556 [PMID: 17006999 DOI: 10.3748/wjg.v12.i34.5554] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
114 Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourlière M, Renou C, Tran A, Melin P, Hézode C, Chevalier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006;131:1040-8. [PMID: 17030174 DOI: 10.1053/j.gastro.2006.07.022] [Cited by in Crossref: 139] [Cited by in F6Publishing: 124] [Article Influence: 8.7] [Reference Citation Analysis]
115 Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384:414-426. [PMID: 24907224 DOI: 10.1016/s0140-6736(14)60538-9] [Cited by in Crossref: 272] [Cited by in F6Publishing: 122] [Article Influence: 34.0] [Reference Citation Analysis]
116 Gaajetaan GR, Bruggeman CA, Stassen FR. The type I interferon response during viral infections: a "SWOT" analysis. Rev Med Virol 2012;22:122-37. [PMID: 21971992 DOI: 10.1002/rmv.713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
117 Pan Q, Tilanus HW, Janssen HL, van der Laan LJ. Prospects of RNAi and microRNA-based therapies for hepatitis C. Expert Opinion on Biological Therapy 2009;9:713-24. [DOI: 10.1517/14712590902989970] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
118 Hopwood M, Treloar C. The experience of interferon-based treatments for hepatitis C infection. Qual Health Res 2005;15:635-46. [PMID: 15802540 DOI: 10.1177/1049732304273932] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
119 Zhang J, Zhu M, Lin Y, Zhou H. The synthesis of benzoxaboroles and their applications in medicinal chemistry. Sci China Chem 2013;56:1372-81. [DOI: 10.1007/s11426-013-4981-y] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
120 Naffah F. Patients with hepatitis C are best managed by a specialist in liver diseases. CON: The management of hepatitis C in a community-based practice. Am J Gastroenterol 2007;102:1839-41. [PMID: 17727426 DOI: 10.1111/j.1572-0241.2007.01433_3.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
121 Feuth T, Arends JE, Lieveld FI, Mundt MW, Hoepelman AI, Siersema PD, van Erpecum KJ. Impact of transient elastography on clinical decision-making in patients with chronic viral hepatitis. Scand J Gastroenterol 2013;48:1074-81. [PMID: 23886398 DOI: 10.3109/00365521.2013.819441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
122 Xie X, Zhang L, Chen YZ. Association between IFNL4 rs368234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon/ribavirin therapy: A meta-analysis. Hum Immunol 2016;77:609-15. [PMID: 27180197 DOI: 10.1016/j.humimm.2016.05.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
123 Konerman MA, Lok AS. Interferon Treatment for Hepatitis B. Clin Liver Dis. 2016;20:645-665. [PMID: 27742005 DOI: 10.1016/j.cld.2016.06.002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
124 Horigome H, Takezono Y, Fujino N, Uchida A, Murasaki G. [A case of ischemic colitis associated with interferon treatment]. Nihon Shokakibyo Gakkai Zasshi 1996;93:181-4. [PMID: 8721113 [PMID: 8721113 DOI: 10.1111/j.1365-2893.2011.01501.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
125 . EASL Recommendations on Treatment of Hepatitis C 2014. Journal of Hepatology 2014;61:373-95. [DOI: 10.1016/j.jhep.2014.05.001] [Cited by in Crossref: 128] [Cited by in F6Publishing: 134] [Article Influence: 16.0] [Reference Citation Analysis]
126 Kozielewicz D, Dybowska D, Karwowska K, Wietlicka-Piszcz M. Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors. Expert Opin Drug Saf. 2015;14:1815-1825. [PMID: 26513231 DOI: 10.1517/14740338.2015.1102882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
127 De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res. 2003;58:1-16. [PMID: 12719002 DOI: 10.1016/s0166-3542(03)00028-7] [Cited by in Crossref: 139] [Cited by in F6Publishing: 34] [Article Influence: 7.3] [Reference Citation Analysis]
128 Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin. Aliment Pharmacol Ther. 2012;36:91-103. [PMID: 22591106 DOI: 10.1111/j.1365-2036.2012.05131.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
129 Bruno S, Cammà C, Di Marco V, Rumi M, Vinci M, Camozzi M, Rebucci C, Di Bona D, Colombo M, Craxì A. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol. 2004;41:474-481. [PMID: 15336451 DOI: 10.1016/j.jhep.2004.05.012] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 4.4] [Reference Citation Analysis]
130 Neukam K, Macías J, Mira JA, Pineda JA. A review of current anti-HCV treatment regimens and possible future strategies. Expert Opinion on Pharmacotherapy 2009;10:417-33. [DOI: 10.1517/14656560802694481] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
131 Wahid B, Rafique S, Saleem K, Ali A, Idrees M. An Increase in Expression of SOCS1 Gene with Increase in Hepatitis C Virus Viral Load. Journal of Interferon & Cytokine Research 2018;38:122-8. [DOI: 10.1089/jir.2017.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
132 Zhao X, Qian Y, Li GJ, Tan J. Preventive effects of the polysaccharide of Larimichthys crocea swim bladder on carbon tetrachloride (CCl4)-induced hepatic damage. Chin J Nat Med 2015;13:521-8. [PMID: 26233842 DOI: 10.1016/S1875-5364(15)30046-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
133 Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol. 2013;11:1503-1510. [PMID: 23707354 DOI: 10.1016/j.cgh.2013.05.014] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 5.4] [Reference Citation Analysis]
134 Fusco F, D'anzeo G, Rossi A, Sciorio C, Buonomo AR, d'Emmanuele di Villa Bianca R, Borgia G, Mirone V, Gentile I. Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature. Expert Opinion on Pharmacotherapy 2013;14:2533-44. [DOI: 10.1517/14656566.2013.850073] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
135 Boglione L, Cardellino CS, Cusato J, De Nicolò A, Cariti G, Di Perri G, D'Avolio A. Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study. Infect Genet Evol 2017;51:167-72. [PMID: 28315743 DOI: 10.1016/j.meegid.2017.03.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
136 Núñez M, Soriano V. New Hopes for HIV and HCV Coinfection in 2004. HIV Clinical Trials 2015;5:232-51. [DOI: 10.1310/geuc-ngkm-xugu-4x94] [Cited by in Crossref: 6] [Article Influence: 0.9] [Reference Citation Analysis]
137 Tsai MC, Lin MC, Hung CH. Successful antiviral and antituberculosis treatment with pegylated interferon-alfa and ribavirin in a chronic hepatitis C patient with pulmonary tuberculosis. J Formos Med Assoc 2009;108:746-50. [PMID: 19773215 DOI: 10.1016/S0929-6646(09)60400-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
138 Castéra L, Constant A, Henry C, Couzigou P. Manifestations psychiatriques au cours du traitement de l’hépatite chronique C. Gastroentérologie Clinique et Biologique 2005;29:123-33. [DOI: 10.1016/s0399-8320(05)80714-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
139 Fumaz CR, Muñoz-moreno JA, Ballesteros AL, Paredes R, Ferrer MJ, Salas A, Fuster D, Masmitjà E, Pérez-álvarez N, Gómez G, Tural C, Clotet B. Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients. AIDS Care 2007;19:138-45. [DOI: 10.1080/09540120600645539] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
140 Jeffers LJ. Treating hepatitis C in African Americans. Liver Int 2007;27:313-22. [PMID: 17355451 DOI: 10.1111/j.1478-3231.2006.01438.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
141 Marcellin P, Roberts SK, Reddy KR, Harrison SA, Jensen DM, Hadziyannis S, Diago M, Weltman M, Messinger D, Tatsch F. Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opin Drug Saf. 2012;11:901-909. [PMID: 22943161 DOI: 10.1517/14740338.2012.721927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
142 Klein MB, Cooper C, Brouillette MJ, Sheehan NL, Benkelfat C, Annable L, Weston F, Kraus D, Singer J. CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. Contemp Clin Trials. 2008;29:617-630. [PMID: 18262853 DOI: 10.1016/j.cct.2008.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
143 Kong D, Liu Y, Wang Z, Jiang L, Cheng J, Xu L, Zhuang Q, Lu C, Chi Y, Wei Q. Establishment of an electrochemiluminescence quenching method for ribavirin detection in Ru(bpy) 3 2+ /TEA system. Journal of Electroanalytical Chemistry 2017;801:1-6. [DOI: 10.1016/j.jelechem.2017.07.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
144 Hametner S, Monticelli F, Kern JM, Schöfl R, Ziachehabi A, Maieron A. Tuberculous sepsis during antiviral HCV triple therapy. Journal of Hepatology 2013;59:637-8. [DOI: 10.1016/j.jhep.2013.05.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
145 Middleton T, He Y, Pilot-Matias T, Tripathi R, Lim BH, Roth A, Chen CM, Koev G, Ng TI, Krishnan P, Pithawalla R, Mondal R, Dekhtyar T, Lu L, Mo H, Kati WM, Molla A. A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations. J Virol Methods 2007;145:137-45. [PMID: 17604129 DOI: 10.1016/j.jviromet.2007.05.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
146 Overbeck K, Bruggmann P, Helbling B. Chronic Hepatitis C virus infection in Swiss primary care practices: Low case loads—high barriers to treatment? European Journal of General Practice 2011;17:103-8. [DOI: 10.3109/13814788.2010.545122] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
147 Zupin L, Polesello V, Alberi G, Moratelli G, Crocè SL, Masutti F, Pozzato G, Crovella S, Segat L. CD209 promoter polymorphisms associate with HCV infection and pegylated-interferon plus ribavirin treatment response. Mol Immunol 2016;76:49-54. [PMID: 27348632 DOI: 10.1016/j.molimm.2016.06.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
148 Jarlais DC, Cooper HL, Bramson H, Deren S, Hatzakis A, Hagan H. Racial and ethnic disparities and implications for the prevention of HIV among persons who inject drugs. Curr Opin HIV AIDS 2012;7:354-61. [PMID: 22498481 DOI: 10.1097/COH.0b013e328353d990] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
149 Wei C, Grace JE Jr, Zvyaga TA, Drexler DM. Utility of high-resolution accurate MS to eliminate interferences in the bioanalysis of ribavirin and its phosphate metabolites. Bioanalysis 2012;4:1895-905. [PMID: 22943620 DOI: 10.4155/bio.12.151] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
150 Piccinino F, Coppola N. Antiviral treatment of HCV-related cirrhosis. Digestive and Liver Disease 2007;39:S96-S101. [DOI: 10.1016/s1590-8658(07)80019-3] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
151 Marcellin F, Demoulin B, Spire B, Suzan-Monti M, Roux P, Protopopescu C, Sagaon-Teyssier L, Duracinsky M, Dray-Spira R, Carrieri MP; ANRS-VESPA2 Study Group. Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study). Expert Rev Gastroenterol Hepatol 2015;9:701-13. [PMID: 25723557 DOI: 10.1586/17474124.2015.1016914] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
152 Mchutchison JG, Dev AT. Future trends in managing hepatitis C. Gastroenterology Clinics of North America 2004;33:51-61. [DOI: 10.1016/j.gtc.2003.12.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
153 Chien CH, Lin CL, Hu CC, Chang JJ, Chien RN. Clearance of Hepatitis C Virus Improves Insulin Resistance During and After Peginterferon and Ribavirin Therapy. J Interferon Cytokine Res. 2015;35:981-989. [PMID: 26308911 DOI: 10.1089/jir.2014.0200] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
154 Quarantini LC, Bressan RA, Galvão A, Batista-neves S, Paraná R, Miranda-scippa Â. Incidence of psychiatric side effects during pegylated interferon- ? retreatment in nonresponder hepatitis C virus-infected patients. Liver Int 2007;27:1098-102. [DOI: 10.1111/j.1478-3231.2007.01532.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
155 Festi D, Sandri L, Mazzella G, Roda E, Sacco T, Staniscia T, Capodicasa S, Vestito A, Colecchia A. Safety of interferon β treatment for chronic HCV hepatitis. World J Gastroenterol 2004; 10(1): 12-16 [PMID: 14695760 DOI: 10.3748/wjg.v10.i1.12] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
156 Buster EH, Schalm SW, Janssen HL. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. Best Pract Res Clin Gastroenterol. 2008;22:1093-1108. [PMID: 19187869 DOI: 10.1016/j.bpg.2008.11.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
157 Goh PG, Kim MJ, Kim HJ, Eun HS, Kim ES, Kim YJ, Lee SY, Moon HS, Lee ES, Kim SH, Lee BS, Lee HY. Importance of Medication Adherence to Peginterferon-Ribavirin Combination Therapy in Patients with Chronic Hepatitis C. Korean J Gastroenterol 2011;57:294. [DOI: 10.4166/kjg.2011.57.5.294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
158 Hu C, Weng C, Lin C, Tien H, Kuo Y, Chien C, Yen C, Lin C, Chien R. Predictors of Changes in Hemoglobin Levels in Patients with Chronic Hepatitis C Treated with Ribavirin Plus Pegylated Interferon-α. Renal Failure 2012;34:429-34. [DOI: 10.3109/0886022x.2011.650562] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
159 Qi X, Bae A, Liu S, Yang H, Sun S, Harris J, Delaney W, Miller M, Mo H. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates. Antiviral Research 2009;81:166-73. [DOI: 10.1016/j.antiviral.2008.11.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
160 Marcellin F, Roux P, Protopopescu C, Duracinsky M, Spire B, Carrieri MP. Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Rev Gastroenterol Hepatol 2017;11:259-68. [PMID: 28116926 DOI: 10.1080/17474124.2017.1285227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
161 Makowska Z, Heim MH. Interferon signaling in the liver during hepatitis C virus infection. Cytokine 2012;59:460-6. [DOI: 10.1016/j.cyto.2012.06.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
162 Doyle JS, Hellard ME, Thompson AJ. The role of viral and host genetics in natural history and treatment of chronic HCV infection. Best Pract Res Clin Gastroenterol. 2012;26:413-427. [PMID: 23199501 DOI: 10.1016/j.bpg.2012.09.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
163 Fidock MD, Souberbielle BE, Laxton C, Rawal J, Delpuech-Adams O, Corey TP, Colman P, Kumar V, Cheng JB, Wright K, Srinivasan S, Rana K, Craig C, Horscroft N, Perros M, Westby M, Webster R, van der Ryst E. The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther 2011;89:821-9. [PMID: 21451504 DOI: 10.1038/clpt.2011.60] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
164 Fujita N, Horiike S, Sugimoto R, Tanaka H, Iwasa M, Kobayashi Y, Hasegawa K, Ma N, Kawanishi S, Adachi Y. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients. Free Radic Biol Med. 2007;42:353-362. [PMID: 17210448 DOI: 10.1016/j.freeradbiomed.2006.11.001] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 3.9] [Reference Citation Analysis]
165 Raboisson P, Lin T, Kock HD, Vendeville S, Vreken WVD, Mcgowan D, Tahri A, Hu L, Lenz O, Delouvroy F, Surleraux D, Wigerinck P, Nilsson M, Rosenquist Å, Samuelsson B, Simmen K. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors. Bioorganic & Medicinal Chemistry Letters 2008;18:5095-100. [DOI: 10.1016/j.bmcl.2008.07.124] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
166 Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. J Gastroenterol Hepatol. 2012;27:1233-1240. [PMID: 22098185 DOI: 10.1111/j.1440-1746.2011.06965.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
167 Wu JZ, Yeh L, Lin C, Hong Z. Conversion of Viramidine to Ribavirin in Vivo by Adenosine Deaminase and its Inhibition by 2′-Deoxycoformycin. Antivir Chem Chemother 2006;17:33-9. [DOI: 10.1177/095632020601700105] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
168 Gish RG. Treating hepatitis C: the state of the art. Gastroenterol Clin North Am. 2004;33:S1-S9. [PMID: 15081099 DOI: 10.1016/j.gtc.2003.12.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
169 Ferenci P. Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future. Expert Opin Drug Saf. 2011;10:529-544. [PMID: 21345149 DOI: 10.1517/14740338.2011.555079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
170 Bacon BR. Assessing evidence from clinical trials in chronic hepatitis C. J Viral Hepat 2006;13 Suppl 1:1-5. [PMID: 16630041 DOI: 10.1111/j.1365-2893.2006.00755.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
171 Stansfield I, Pompei M, Conte I, Ercolani C, Migliaccio G, Jairaj M, Giuliano C, Rowley M, Narjes F. Development of carboxylic acid replacements in indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase. Bioorg Med Chem Lett 2007;17:5143-9. [PMID: 17681757 DOI: 10.1016/j.bmcl.2007.06.093] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
172 Lodato F, Tamé MR, Colecchia A, Racchini C, Azzaroli F, D’Errico A, Casanova S, Pinna A, Roda E, Mazzella G. Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence. World J Gastroenterol 2006; 12(26): 4253-4255 [PMID: 16830387 DOI: 10.3748/wjg.v12.i26.4253] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
173 Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124:1711-1719. [PMID: 12761728 DOI: 10.1016/s0016-5085(03)00394-9] [Cited by in Crossref: 185] [Cited by in F6Publishing: 76] [Article Influence: 9.7] [Reference Citation Analysis]
174 Postal Pavan MH, Pavin EJ, Gonçales FL, Zantut Wittmann DE. Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C. The Brazilian Journal of Infectious Diseases 2011;15:449-56. [DOI: 10.1016/s1413-8670(11)70226-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
175 Homoncik M, Sieghart W, Formann E, Schmid M, Ferenci P, Gangl A, Jilma B, Peck-radosavljevic M. Erythropoietin Treatment Is Associated with More Severe Thrombocytopenia in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy. Am J Gastroenterology 2006;101:2275-82. [DOI: 10.1111/j.1572-0241.2006.00774.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
176 Adinolfi LE, Durante-mangoni E, Salzillo M, Marrone A, Tripodi M, Restivo L, Merola A, Zampino R, Ruggiero G. Leukocyte interferon-α and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon. Intern Emerg Med 2009;4:485-90. [DOI: 10.1007/s11739-009-0290-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
177 Fioravanti J, González I, Medina-echeverz J, Larrea E, Ardaiz N, González-aseguinolaza G, Prieto J, Berraondo P. Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties. Hepatology 2011;53:1864-73. [DOI: 10.1002/hep.24306] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
178 Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ. Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States. Clin Ther 2015;37:1713-25.e3. [PMID: 26111918 DOI: 10.1016/j.clinthera.2015.05.503] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
179 Hallinan R, Byrne A, Agho K, Dore GJ. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend. 2007;88:49-53. [PMID: 17067763 DOI: 10.1016/j.drugalcdep.2006.09.018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
180 Lima MA, Auriel E, Wüthrich C, Borenstein NM, Koralnik IJ. Progressive multifocal leukoencephalopathy as a complication of hepatitis C virus treatment in an HIV-negative patient. Clin Infect Dis 2005;41:417-9. [PMID: 16007550 DOI: 10.1086/431769] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
181 Strauss E, Dias Teixeira MC. Quality of life in hepatitis C. Liver Int. 2006;26:755-765. [PMID: 16911456 DOI: 10.1111/j.1478-3231.2006.01331.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 2.9] [Reference Citation Analysis]
182 Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Controlled Clinical Trials 2004;25:472-92. [DOI: 10.1016/j.cct.2004.08.003] [Cited by in Crossref: 122] [Cited by in F6Publishing: 114] [Article Influence: 6.8] [Reference Citation Analysis]
183 Meller S, Gerber PA, Kislat A, Hevezi P, Göbel T, Wiesner U, Kellermann S, Bünemann E, Zlotnik A, Häussinger D, Erhardt A, Homey B. Allergic sensitization to pegylated interferon-α results in drug eruptions. Allergy 2015;70:775-83. [PMID: 25831972 DOI: 10.1111/all.12618] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
184 Olson M, Jacobson IM. Role of the nurse practitioner in the management of patients with chronic hepatitis C: Chronic hepatitis C management of side. Journal of the American Academy of Nurse Practitioners 2011;23:410-20. [DOI: 10.1111/j.1745-7599.2011.00603.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
185 Dadgostari S, Xu C, Yeh L, Lin CC, Vitarella D. Viramidine Demonstrates Better Safety Than Ribavirin in Monkeys But Not Rats. Drug and Chemical Toxicology 2004;27:191-211. [DOI: 10.1081/dct-200031953] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
186 Shin SR, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW. Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response. J Gastroenterol Hepatol. 2010;25:957-963. [PMID: 20546450 DOI: 10.1111/j.1440-1746.2009.06176.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
187 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2014;20:89-136. [PMID: 25032178 DOI: 10.3350/cmh.2014.20.2.89] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
188 Wang H, Wu H, Bao S, Xiang X, Zhao G, Liu K, Li F, Xu Y, An B, Zhou H, Lu J, Xie Q. Association of IPS1 polymorphisms with peginterferon efficacy in chronic hepatitis B with HBeAg-positive in the Chinese population. Infect Genet Evol 2015;31:161-8. [PMID: 25640825 DOI: 10.1016/j.meegid.2015.01.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
189 Farnik H, Lange CM, Sarrazin C, Kronenberger B, Zeuzem S, Herrmann E. Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Clinical Gastroenterology and Hepatology 2010;8:884-90. [DOI: 10.1016/j.cgh.2010.06.019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
190 Sabbatani S, Manfredi R, Marinacci G, Pavoni M, Cristoni L, Chiodo F. Reactivation of severe, acute pulmonary tuberculosis during treatment with pegylated interferon-alpha and ribavirin for chronic HCV hepatitis. Scand J Infect Dis. 2006;38:205-208. [PMID: 16500782 DOI: 10.1080/00365540500263268] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
191 Innes H, Goldberg D, Dusheiko G, Hayes P, Mills PR, Dillon JF, Aspinall E, Barclay ST, Hutchinson SJ. Patient-important benefits of clearing the hepatitis C virus through treatment: A simulation model. Journal of Hepatology 2014;60:1118-26. [DOI: 10.1016/j.jhep.2014.01.020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
192 Afdhal NH. Role of epoetin alfa in maintaining ribavirin dose. Gastroenterology Clinics of North America 2004;33:25-35. [DOI: 10.1016/j.gtc.2003.12.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
193 Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy. Int J Infect Dis. 2015;30:91-97. [PMID: 25462177 DOI: 10.1016/j.ijid.2014.09.021] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
194 Larrey D, Couzigou P, Denis J. Hépatite chronique C : gestion des effets indésirables du traitement. Gastroentérologie Clinique et Biologique 2007;31:20-8. [DOI: 10.1016/s0399-8320(07)92559-2] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
195 Hsu CS, Kao JH. Genomic variation-guided management in chronic hepatitis C. Expert Rev Gastroenterol Hepatol 2012;6:497-506. [PMID: 22928901 DOI: 10.1586/egh.12.24] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
196 Rudd MT, Mccauley JA, Romano JJ, Butcher JW, Bush K, Mcintyre CJ, Nguyen KT, Gilbert KF, Lyle TA, Holloway MK, Wan B, Vacca JP, Summa V, Harper S, Rowley M, Carroll SS, Burlein C, Dimuzio JM, Gates A, Graham DJ, Huang Q, Ludmerer SW, Mcclain S, Mchale C, Stahlhut M, Fandozzi C, Taylor A, Trainor N, Olsen DB, Liverton NJ. Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease. Bioorganic & Medicinal Chemistry Letters 2012;22:7201-6. [DOI: 10.1016/j.bmcl.2012.08.106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
197 Reiberger T, Rutter K, Ferlitsch A, Payer BA, Hofer H, Beinhardt S, Kundi M, Ferenci P, Gangl A, Trauner M. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol. 2011;9:602-608.e1. [PMID: 21397726 DOI: 10.1016/j.cgh.2011.03.002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
198 Allegra S, Cusato J, De Nicolò A, Boglione L, Gatto A, Cariti G, Di Perri G, D'Avolio A. Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients. Biomed Pharmacother 2015;69:47-55. [PMID: 25661337 DOI: 10.1016/j.biopha.2014.10.030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
199 Maida I, Soriano V, Ramos B, Ríos P, González-lahoz J, Núñez M. Characteristics and Prospects for Hepatitis C Therapy of an HIV-HCV Coinfected Population Followed at a Reference HIV Center. HIV Clinical Trials 2015;6:329-36. [DOI: 10.1310/25kl-0vtl-jwxp-fe6y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 1.9] [Reference Citation Analysis]
200 Sulkowski MS, Felizarta F, Smith C, Slim J, Berggren R, Goodman R, Ball L, Khalili M, Dieterich DT; Hepatitis Resource Network Clinical Trials Group. Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial. J Acquir Immune Defic Syndr 2004;35:464-72. [PMID: 15021311 DOI: 10.1097/00126334-200404150-00004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
201 Coppola N, Pisaturo M, Sagnelli C, Onorato L, Sagnelli E. Role of genetic polymorphisms in hepatitis C virus chronic infection. World J Clin Cases 2015; 3(9): 807-822 [PMID: 26380828 DOI: 10.12998/wjcc.v3.i9.807] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
202 Li PY, Zhou XJ, Yao L, Fang XH, Ren JN, Song JW. Novel biosensor-based microarray assay for detecting rs8099917 and rs12979860 genotypes. World J Gastroenterol 2012; 18(44): 6481-6488 [PMID: 23197895 DOI: 10.3748/wjg.v18.i44.6481] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
203 Liebman H. Other immune thrombocytopenias. Semin Hematol. 2007;44:S24-S34. [PMID: 18096469 DOI: 10.1053/j.seminhematol.2007.11.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
204 Calvaruso V, Mazza M, Almasio PL. Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects. Expert Opin Drug Saf 2011;10:429-35. [PMID: 21323500 DOI: 10.1517/14740338.2011.559161] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
205 Stribling R, Sussman N, Vierling JM. Treatment of hepatitis C infection. Gastroenterol Clin North Am. 2006;35:463-486. [PMID: 16880075 DOI: 10.1016/j.gtc.2006.05.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
206 Martinez-Camacho A, Khaoustov VI, Adam E, Lewis DE, Tavakoli-Tabasi S, Yoffe B. Lymphocytosis as a predictor of poor response to treatment of hepatitis C. Clin Res Hepatol Gastroenterol 2011;35:34-40. [PMID: 21185139 DOI: 10.1016/j.gcb.2010.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
207 Budhram A, Cebrian C. Paranoid psychosis and cognitive impairment associated with hepatitis C antiviral therapy. Gen Hosp Psychiatry 2014;36:126.e3-5. [PMID: 24210465 DOI: 10.1016/j.genhosppsych.2013.10.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
208 Rudd MT, Mcintyre CJ, Romano JJ, Butcher JW, Holloway MK, Bush K, Nguyen KT, Gilbert KF, Lyle TA, Liverton NJ, Wan B, Summa V, Harper S, Rowley M, Vacca JP, Carroll SS, Burlein C, Dimuzio JM, Gates A, Graham DJ, Huang Q, Ludmerer SW, Mcclain S, Mchale C, Stahlhut M, Fandozzi C, Taylor A, Trainor N, Olsen DB, Mccauley JA. Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2–P4 linkers. Bioorganic & Medicinal Chemistry Letters 2012;22:7207-13. [DOI: 10.1016/j.bmcl.2012.09.061] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
209 Thompson AJ, Fellay J, Mchutchison JG. How the Human Genome Can Predict Response to Hepatitis C Therapy. Curr Hepatitis Rep 2010;9:1-8. [DOI: 10.1007/s11901-010-0029-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
210 Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Journal of Hepatology 2010;53:455-9. [DOI: 10.1016/j.jhep.2010.04.013] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
211 Paraná R, Schinoni MI, de Freitas LA, Codes L, Cruz M, Andrade Z, Trepo C. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C. Liver Int 2006;26:1148-54. [PMID: 17032416 DOI: 10.1111/j.1478-3231.2006.01345.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
212 Hauser P. Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFNα-induced depression. Gastroenterology Clinics of North America 2004;33:37-50. [DOI: 10.1016/j.gtc.2003.12.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
213 Hughes CA, Shafran SD. Chronic hepatitis C virus management: 2000-2005 update. Ann Pharmacother. 2006;40:74-82. [PMID: 16368925 DOI: 10.1345/aph.1g263] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
214 Agnesod D, De Nicolò A, Simiele M, Mohamed Abdi A, Boglione L, Di Perri G, D'Avolio A. Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients. J Pharm Biomed Anal 2014;90:119-26. [PMID: 24366212 DOI: 10.1016/j.jpba.2013.11.027] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
215 Weigand K, Stremmel W, Encke J. Treatment of hepatitis C virus infection. World J Gastroenterol 2007; 13(13): 1897-1905 [PMID: 17461488 DOI: 10.3748/wjg.v13.i13.1897] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
216 Alfageme Michavila I, Merino Sánchez M, Pérez Ronchel J, Lara Lara I, Suárez García E, López Garrido J. Sarcoidosis Following Combined Ribavirin and Interferon Therapy: a Case Report and Review of the Literature. Archivos de Bronconeumología ((English Edition)) 2004;40:45-9. [DOI: 10.1016/s1579-2129(06)60192-4] [Cited by in Crossref: 10] [Article Influence: 0.6] [Reference Citation Analysis]
217 Banerjee D, Reddy KR. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther. 2016;43:674-696. [PMID: 26787287 DOI: 10.1111/apt.13514] [Cited by in Crossref: 99] [Cited by in F6Publishing: 88] [Article Influence: 16.5] [Reference Citation Analysis]
218 Andrade R. Manejo de los efectos adversos del tratamiento. Gastroenterología y Hepatología 2006;29:184-9. [DOI: 10.1157/13097657] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
219 Kumada H, daCosta Dibonaventura M, Yuan Y, Kalsekar A, Kopenhafer L, Tang A, Victor TW, L’italien G, Chayama K, Toyota J. The Patient-Related Burden of Pegylated-Interferon-α Therapy and Adverse Events among Patients with Viral Hepatitis C in Japan. Value in Health Regional Issues 2014;3:50-8. [DOI: 10.1016/j.vhri.2014.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
220 Hsu C, Hsu S, Chen H, Liu C, Jeng J, Liu C, Chen P, Chen D, Kao J. Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients. Hepatol Int 2013;7:171-9. [DOI: 10.1007/s12072-012-9390-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
221 Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, Herrine SK, Harrison SA, Poordad FF, Koury K. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology. 2010;139:1602-1611, 1611.e1. [PMID: 20723545 DOI: 10.1053/j.gastro.2010.07.059] [Cited by in Crossref: 85] [Cited by in F6Publishing: 74] [Article Influence: 7.1] [Reference Citation Analysis]
222 Paradis V, Asselah T, Dargere D, Ripault MP, Martinot M, Boyer N, Valla D, Marcellin P, Bedossa P. Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin. Gastroenterology. 2006;130:2189-2197. [PMID: 16762639 DOI: 10.1053/j.gastro.2006.02.059] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
223 Sun SC, Bae A, Qi X, Harris J, Wong KA, Miller MD, Mo H. Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates. J Viral Hepat. 2011;18:861-870. [PMID: 21108698 DOI: 10.1111/j.1365-2893.2010.01396.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
224 Gluhovschi C, Gadalean F, Kaycsa A, Curescu M, Sporea I, Gluhovschi G, Petrica L, Velciov S, Bozdog G, Bob F. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects? Immunopharmacol Immunotoxicol. 2011;33:744-750. [PMID: 21320001 DOI: 10.3109/08923973.2010.551129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
225 Kang JS, Deluca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs 2009;14:363-80. [PMID: 19453284 DOI: 10.1517/14728210902907847] [Cited by in Crossref: 188] [Cited by in F6Publishing: 166] [Article Influence: 14.5] [Reference Citation Analysis]
226 Kolor B. Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic. Pharmacotherapy 2005;25:1230-41. [PMID: 16164396 DOI: 10.1592/phco.2005.25.9.1230] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
227 Dragovich PS, Blazel JK, Ellis DA, Han Q, Kamran R, Kissinger CR, LeBrun LA, Li LS, Murphy DE, Noble M, Patel RA, Ruebsam F, Sergeeva MV, Shah AM, Showalter RE, Tran CV, Tsan M, Webber SE, Kirkovsky L, Zhou Y. Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents. Bioorg Med Chem Lett 2008;18:5635-9. [PMID: 18796353 DOI: 10.1016/j.bmcl.2008.08.094] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
228 Li X, Zhang S, Zhang Y, Liu Y, Ding CZ, Zhou Y, Plattner JJ, Baker SJ, Bu W, Liu L, Kazmierski WM, Duan M, Grimes RM, Wright LL, Smith GK, Jarvest RL, Ji J, Cooper JP, Tallant MD, Crosby RM, Creech K, Ni Z, Zou W, Wright J. Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties. Bioorganic & Medicinal Chemistry Letters 2011;21:2048-54. [DOI: 10.1016/j.bmcl.2011.02.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
229 Murakami Y, Nagai A, Kawakami T, Hino K, Kitase A, Hara Y, Okuda M, Okita K, Okita M. Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon alpha-2b and ribavirin. Nutrition. 2006;22:114-122. [PMID: 16459223 DOI: 10.1016/j.nut.2005.05.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
230 Rhyne PW, Wong OT, Zhang YJ, Weiner RS. Electrochemiluminescence in bioanalysis. Bioanalysis 2009;1:919-35. [PMID: 21083063 DOI: 10.4155/bio.09.80] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
231 Rudd MT, Butcher JW, Nguyen KT, McIntyre CJ, Romano JJ, Gilbert KF, Bush KJ, Liverton NJ, Holloway MK, Harper S, Ferrara M, DiFilippo M, Summa V, Swestock J, Fritzen J, Carroll SS, Burlein C, DiMuzio JM, Gates A, Graham DJ, Huang Q, McClain S, McHale C, Stahlhut MW, Black S, Chase R, Soriano A, Fandozzi CM, Taylor A, Trainor N, Olsen DB, Coleman PJ, Ludmerer SW, McCauley JA. P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325. ChemMedChem 2015;10:727-35. [PMID: 25759009 DOI: 10.1002/cmdc.201402558] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
232 Laguno M, Sánchez-tapias JM, Murillas J, Forns X, Blanco JL, Martínez E, Larrousse M, León A, Loncá M, Milinkovic A, Miró JM, García F, Gatell JM, Mallolas J. Avances en el diagnóstico y tratamiento de la infección por el VHC en pacientes con y sin infección por el VIH. Enfermedades Infecciosas y Microbiología Clínica 2005;23:32-40. [DOI: 10.1157/13070408] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
233 Hassanien KS, El-Sayed EM, Ismail RS, Zakarya ZM, Helal GK. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients. J Clin Pharm Ther 2021;46:942-9. [PMID: 33768560 DOI: 10.1111/jcpt.13417] [Reference Citation Analysis]
234 Kanda T, Nakamoto S, Wu S, Yokosuka O. Role of IL28B genotype in older hepatitis C virus-infected patients. World J Immunol 2013; 3(3): 54-61 [DOI: 10.5411/wji.v3.i3.54] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
235 Zografos TA, Rigopoulou EI, Liaskos C, Togousidis E, Zachou K, Gatselis N, Germenis A, Dalekos GN. Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis. J Hepatol. 2006;44:848-855. [PMID: 16530290 DOI: 10.1016/j.jhep.2006.01.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
236 Narciso-Schiavon JL, Schiavon Lde L, Carvalho-Filho RJ, Sampaio JP, Batah PN, Barbosa DV, Ferraz ML, Silva AE. Gender influence on treatment of chronic hepatitis C genotype 1. Rev Soc Bras Med Trop 2010;43:217-23. [PMID: 20563484 DOI: 10.1590/s0037-86822010000300001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
237 Ruebsam F, Murphy DE, Tran CV, Li LS, Zhao J, Dragovich PS, McGuire HM, Xiang AX, Sun Z, Ayida BK, Blazel JK, Kim SH, Zhou Y, Han Q, Kissinger CR, Webber SE, Showalter RE, Shah AM, Tsan M, Patel RA, Thompson PA, Lebrun LA, Hou HJ, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Khandurina J, Brooks J, Okamoto E, Kirkovsky L. Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett 2009;19:6404-12. [PMID: 19818610 DOI: 10.1016/j.bmcl.2009.09.045] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
238 Belkahla N, Kchir H, Maamouri N, Ouerghi H, Hariz FB, Chouaib S, Chaabouni H, Mami NB. [Reactivation of tuberculosis during dual therapy with pegylated interferon and ribavirin for chronic hepatitis C]. Rev Med Interne. 2010;31:e1-e3. [PMID: 20605283 DOI: 10.1016/j.revmed.2009.11.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
239 Neuman MG, Monteiro M, Rehm J. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Subst Use Misuse 2006;41:1395-463. [PMID: 17002989 DOI: 10.1080/10826080600846235] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]